CREATE Medicines Announces Promising Clinical Results for In Vivo CAR Therapy in Solid Tumors

Strategic Insights -

Researchers at CREATE Medicines, a clinical-stage biotech company, have reported preliminary clinical results from the Phase 1 MYE Symphony trial of MT-302, an in vivo mRNA-LNP CAR therapy designed to treat solid tumors. The results demonstrate the potential of this approach to overcome the limitations of traditional CAR therapies, which have primarily been used to treat blood cancers. By eluting a targeted immune response against TROP2-expressing tumors, MT-302 could provide patients with systemic, repeat-dose therapies without the complexity and cost barriers of traditional cell therapy.

Key Takeaways:

  • The Phase 1 MYE Symphony trial of MT-302 has shown promising preliminary clinical results, offering potential for a new treatment paradigm in solid tumors.
  • MT-302 is an in vivo mRNA-LNP CAR therapy designed to elicit an adaptive immune response against solid tumors.
  • The therapy programs the immune system to recognize and eliminate TROP2-expressing solid tumors by encoding a TROP2-specific chimeric antigen receptor.
  • MT-302 eliminates the need for ex vivo manipulation or preconditioning, enabling repeat dosing and tunable CAR expression for potent anti-tumor activity.
  • Additional details of the clinical results and methodology will be presented at the SITC Annual Meeting.

Statistics:

  • The Phase 1 MYE Symphony trial of MT-302 is expected to present final results at the SITC Annual Meeting.
  • MT-302 has been designed to elicit an adaptive immune response against TROP2-expressing tumors.
  • The therapy is expected to provide patients with systemic, repeat-dose therapies without the complexity and cost barriers of traditional cell therapy.

Sources:

  • "CREATE Medicines, Inc. Announces Acceptance of Late-Breaking Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) 2025, Nov. 3, 2025, PR Newswire."
  • SITC 2025 Program, Nov. 3, 2025, Society for Immunotherapy of Cancer.
  • "About CREATE Medicines, Nov. 3, 2025, CREATE Medicines, Inc."